Validating Novel, Non-contrast Cardiac MRI Imaging in Haemodialysis Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Leicester
About this trial
There are currently no good ways of measuring levels of scarring in the hearts of patients with advanced kidney disease and patients on dialysis, although recent research has shown a new cardiac MRI technique, called native T1 mapping, may provide a solution to this. To assess the accuracy of this novel technique in dialysis patients, it is essential to undertake a study which compares native T1 mapping to actual levels of scarring in the hearts of patients on dialysis.
Eligibility criteria
Qualifiers
Prevalent haemodialysis patient (more than 3 months)
Active on the supportive care register with anticipated death in the subsequent 12 months
Able to give informed consent
Consent to donation of heart for research following death
Disqualifiers
Contraindication to MRI scan (e.g. pacemaker, incompatible metallic implants, claustrophobia)
Patients with expected or potential infiltrative cardiomyopathy (e.g. amyloidosis)
Unable to give informed consent
Unable to understand written and verbal explanations in English
Trial design
Treatments tested in this trial
- Cardiac MRI scan
- Echocardiogram
- Cardiac explantation
- 48-Hour continuous cardiac monitoring
- Blood samples
Treatment groups
9 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Leicester
Lead sponsor
University Hospitals, Leicester
Collaborator
St George's, University of London
Collaborator
Source ClinicalTrials.gov